(CercleFinance.com) – AstraZeneca announced Friday the approval by the FDA of Calquence tablets for the same indications as those existing for the capsule version of the drug.
The biopharmaceutical group explains that this decision follows the conduct of clinical trials which showed that Calquence tablets and capsules had the same efficacy and safety profile.
The tablet formulation simply has the advantage of being able to be taken with agents that reduce the amount of stomach acid, the laboratory specifies in a press release.
Calquence is currently approved in the United States for several indications, including those for chronic lymphocytic leukemia, the most common in Western adults.
The drug is also licensed for the treatment of mantle cell lymphoma, an aggressive non-Hodgkin’s lymphoma associated with a poor prognosis.
Calquence is a selective inhibitor of Bruton’s tyrosine kinase (BTK), which stimulates the pathways necessary for the proliferation and transport of immune cells.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
